Abstract
Purine nucleoside phosphorylase (PNP) is one of the enzymes comprising the purine salvage pathway, and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2-deoxyribonucleosides. The pivotal role of PNP in T-cell proliferation has been demonstrated in patients with inherited PNP deficiency, where T-cell levels may be 1-3percent of normal. This observation helped establish the critical role of PNP in T-cells and provided a rationale for developing inhibitors of PNP. Inhibitors of PNP may be useful for treating a variety of T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohns disease and T-cell cancers. In this manuscript, the x-ray crystal structure of the PNP enzyme is described. Results of a structure-based drug design program aimed at designing small-molecule inhibitors of PNP are also described. Of the many classes of compounds synthesized, studied and reviewed, only one, the 3-pyridinylmethyl-9-deazaguanine (BCX-34, 39) analog has been used in clinical trials. Both topical and oral formulations of BCX-34 were studied in psoriatic patients and the results of these clinical trials are described.
Keywords: Enzyme Purine Nucleoside Phosphorylase, Human immunodeficiency virus, HIV, PNP enzyume, PNP inhibitors, X ray crystallographic analysis
Current Pharmaceutical Design
Title: Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis
Volume: 6 Issue: 9
Author(s): Philip E. Morris,Jr. and George A. Omura
Affiliation:
Keywords: Enzyme Purine Nucleoside Phosphorylase, Human immunodeficiency virus, HIV, PNP enzyume, PNP inhibitors, X ray crystallographic analysis
Abstract: Purine nucleoside phosphorylase (PNP) is one of the enzymes comprising the purine salvage pathway, and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2-deoxyribonucleosides. The pivotal role of PNP in T-cell proliferation has been demonstrated in patients with inherited PNP deficiency, where T-cell levels may be 1-3percent of normal. This observation helped establish the critical role of PNP in T-cells and provided a rationale for developing inhibitors of PNP. Inhibitors of PNP may be useful for treating a variety of T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohns disease and T-cell cancers. In this manuscript, the x-ray crystal structure of the PNP enzyme is described. Results of a structure-based drug design program aimed at designing small-molecule inhibitors of PNP are also described. Of the many classes of compounds synthesized, studied and reviewed, only one, the 3-pyridinylmethyl-9-deazaguanine (BCX-34, 39) analog has been used in clinical trials. Both topical and oral formulations of BCX-34 were studied in psoriatic patients and the results of these clinical trials are described.
Export Options
About this article
Cite this article as:
Morris,Jr. E. Philip and Omura A. George, Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis, Current Pharmaceutical Design 2000; 6 (9) . https://dx.doi.org/10.2174/1381612003400083
DOI https://dx.doi.org/10.2174/1381612003400083 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A QSAR Study on Some Series of Anticancer Tyrosine Kinase Inhibitors
Medicinal Chemistry Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews Strategies for Novel Therapeutic Approaches Targeting Cytokines and Signaling Pathways of Osteoclasto- and Osteoblastogenesis in the Fight Against Immune-Mediated Bone and Joint Diseases
Current Medicinal Chemistry Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Inhibition of Lysozyme by Taurine Dibromamine
Protein & Peptide Letters The Axis of Thrombospondin-1, Transforming Growth Factor Beta and Connective Tissue Growth Factor: An Emerging Therapeutic Target in Rheumatoid Arthritis
Current Vascular Pharmacology Endocrinology and Immunology of Obesity, Obesity Vaccines
Current Clinical Pharmacology Sensors Based On Carbon Nanotubes and Their Applications: A Review
Current Nanoscience Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Current Drug Targets Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture
Current Drug Metabolism Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science Editorial (Hot Topic: Anti-Inflammatory Drugs and the Heart Special Thematic)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Radioactive Drugs in Drug Development Research: Quality Assurance Issues
Mini-Reviews in Medicinal Chemistry Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Drug Repositioning: A Unique Approach to Refurbish Drug Discovery
Current Drug Discovery Technologies Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Dietary Supplement Use in Patients with Rheumatoid Arthritis in Japan
Current Rheumatology Reviews Bone Diseases Associated with Human Immunodeficiency Virus Infection: Pathogenesis, Risk Factors and Clinical Management
Current Molecular Medicine